Rhythm Pharmaceuticals, Inc.
RYTM· Nasdaq
Released Nov 5, 2024, after the close
10-Q filed Nov 6, 2024, 37 days after period end · 0001558370-24-014532
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $33.25M | $22.50M | $4.28M | $1.03M |
| Net Income | -$43.64M | -$44.16M | -$40.86M | -$35.11M |
| EPS Diluted |
Rhythm Pharmaceuticals, Inc. · CIK 1649904 · Engraved from SEC EDGAR
| -$0.73 |
| -$0.76 |
| -$0.79 |
| -$0.70 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.